Abstract
Children with primary immunodeficiency or chromosomal breakage syndromes are at increased risk of developing non-Hodgkin lymphomas; they cannot tolerate standard chemotherapy regimens. We report two children with diffuse, large, B-cell lymphoma; one had ataxia telangiectasia and one had common variable immunodeficiency. Both were given rituximab, 1 as monotherapy and 1 in combination with a reduced CHOP regimen. Complete remission was obtained in each patient. Use of rituximab as a first-line monotherapy or in conjunction with reduced chemotherapy should be considered to reduce cytotoxic effects.
(c) 2009 Wiley-Liss, Inc.
MeSH terms
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Child, Preschool
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Follow-Up Studies
-
Humans
-
Immunologic Deficiency Syndromes / complications
-
Immunologic Deficiency Syndromes / drug therapy*
-
Immunologic Deficiency Syndromes / immunology*
-
Immunotherapy
-
Lymphoma, Non-Hodgkin / complications
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / immunology*
-
Male
-
Prednisone / therapeutic use
-
Remission Induction
-
Rituximab
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone